#TaiyoHoldings

For the third quarter of the fiscal year ending March 2026, net sales were 103,742 million yen (up 14.4% YoY), operating income was 24,571 million yen (up 36.4% YoY), and net income attributable to owners of parent for the quarter was 17,447 million yen (up 34.6% YoY).

Revised consolidated full-year earnings guidance for the fiscal year ending March 2026 to net sales of 133,000 million yen (up 3.3% from the previous forecast), operating income of 29,600 million yen (up 10.0%), and net income attributable to owners of parent of 20,100 million yen (up 9.2%).

For the cumulative third quarter of FY2026, net sales reached JPY 103,742 million (14% YoY increase), operating income JPY 24,571 million (36% YoY increase), and net income attributable to owners of parent was JPY 17,447 million (35% YoY increase), achieving both revenue and profit growth and prompting an upward revision of the full-year earnings forecast.

As of April 1, 2026, Executive Senior Managing Officer Eiji Sato will be appointed Director of Taiyo Pharma Co., Ltd., and Terumichi Tawara will be transferred to Director of the same company.